The PRWIRE Press Releases https:// 2019-03-22T05:17:24Z MedAdvisor partners with Adheris Health, the leading US provider of dynamic patient adherence and engagement solutions, to accelerate rollout in US market 2019-03-22T05:17:24Z medadvisor-partners-with-adheris-health-the-leading-us-provider-of-dynamic-patient-adherence-and-engagement-solutions-to-accelerate-rollout-in-us-market MedAdvisor partners with Adheris Health, the leading US provider of dynamic patient adherence and engagement solutions, to accelerate rollout in US market Melbourne, 22 March, 2019 - MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication management company, is pleased to announce it has signed an initial 12-month Digital Partnership Agreement with Adheris Health, the leading provider of dynamic patient adherence and engagement solutions. The relationship/partnership will offer extended digital adherence programs to Adheris Health’s pharmaceutical clients and across its retail pharmacy network. About Adheris Health Adheris Health, a Syneos Health Company, is a leading provider of dynamic patient adherence and engagement solutions. With customised patient behavioural models built on extensive data insights and analytics, Adheris Health has the ability to communicate with varying patient types as they move throughout their individual patient journeys – in the doctor’s office, at the pharmacy and in their home – through their extensive and proprietary data-driven platform. By targeting patients at the intersections of care with unique, dynamic, adaptable programs, patients receive the comprehensive support required to continue with therapy, resulting in improved success for all stakeholders – patients, providers and brands.  Adheris Health currently reaches over 197m patients on behalf of 26,000+ pharmacies, and has the largest network for patient and prescriber access in the US with access to 197 million patients, 295k prescribers, and direct access to 2.2 billion prescriptions per year. Adheris Health is part of Syneos Health, a US$7B company listed on Nasdaq (Nasdaq:SYNH) that provides integrated clinical and commercial solutions to biopharmaceutical customers Digital Partnership Agreement The initial 12-month Digital Partnership Agreement focuses on extending Adheris Health’s current suite of adherence and engagement solutions to include SMS & web-based offerings powered by MedAdvisor. There has been expressed strong interest from the US pharmaceutical market in increasing their reach through digital channels and the partnership is expected to generate revenue in CY19. MedAdvisor will derive revenue in a similar way to Australia for Patient Engagement Programs that are sold to large pharmaceutical companies in Australia. MedAdvisor will charge a set up fee and a per patient fee relating to the size and complexity of the campaign. Building upon the Australian experience of these types of programs in improving medication adherence in target patient pools, MedAdvisor and Adheris Health will explore the impact of multidimensional communications on patient behaviour. MedAdvisor’s timely investment in globalising its product platform over the past 6 months has been crucial in enabling it to enter this partnership and to support the sophisticated requirements of US-centric medication adherence and engagement programs. Keith Kiarsis, President of MedAdvisor Welam USA, commented: “Adheris Health has been the US leader in patient adherence and engagement programs for over 25 years. They have generated significant revenue from their proprietary and patented technology, patient delivery systems and measurement. These programs have demonstrated significant adherence improvement across virtually all classes of medications dispensed through retail chains. Through this partnership MedAdvisor will be able to combine our market leading digital capabilities with Adheris Health’s impressive network scale and extensive patient performance and clinical program design expertise. The resulting combination will be an unmatched multidimensional approach to patient support in the US, a market more than 10 times the size of Australia.” Robert Read, CEO of MedAdvisor, added: “We have been working toward this moment for the past 6 months. Aside from investing in business development in the US, we have significantly evolved our Australian product into a global product that meets ISO27001 security standard and US HIPAA regulations. Furthermore, the investment in globalising our technology platform is beneficial in the US, in Asia via our joint venture with Zuellig Pharma (previously announced) and in time, in Australia.  It is validating for our global expansion strategy that Adheris Health, the leader in dynamic patient adherence and engagement solutions in the largest pharmaceutical market in the world, has chosen to partner with MedAdvisor for expanded digital solutions for their clients, and we look forward to working with them now and in the years to come.”   Michael Skovira, President of Adheris Health, commented: “By bringing together Adheris Health’s extensive reach and deep adherence knowledge with MedAdvisor’s digital offering, we’re creating a better patient experience at scale. By adding this innovative digital capability to our suite of dynamic patient performance solutions, we’ll have the ability to provide customers with even more opportunities to influence positive patient behavior and drive improved outcomes.”   The parties will begin to market the programs from March 2019 with programs and revenue expected to commence in Q3 CY19. ---ENDS---   For more information   Jennifer Duraisingam Corporate Communications Manager Tel: +61 3 9095 3036 jenniferd@medadvisor.com.au   About MedAdvisor MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. Founded with a desire to simplify medication management, the highly automated and intuitive Australian software system connects patients to their community pharmacy, providing them with real time access to their personal medication records. Available free on mobile and internet devices, the platform also incorporates a variety of valuable and convenient features including reminders and pre-ordering of medications, which together improves adherence to chronic medications by approximately 20%. Since launching in 2013, MedAdvisor has welcomed over one million users through its connections with ~55% of pharmacies and a network of thousands of GPs across Australia. MedAdvisor was recognised in the 2018 AFR Fast 100 at position 23. MedAdvisor Welam is the operating name of MedAdvisor in the USA and it is promoted as Welam Health.   About Adheris Health Adheris Health, a Syneos Health™ company, provides dynamic patient performance programs that activate patients, improve outcomes and elevate brand performance. By leveraging the largest comprehensive networks for patient and prescriber access in the US, we support the patient through the most critical moments of care to ensure they stay on their prescribed therapy to maximize both brand and patient performance.  Learn more at adherishealth.com. InterSystems IRIS for Health Empowers MediWay Technology to Accelerate the Digital Transformation of Healthcare in China 2019-03-19T23:30:26Z intersystems-iris-for-health-empowers-mediway-technology-to-accelerate-the-digital-transformation-of-healthcare-in-china SYDNEY, Australia, March 20, 2019 – InterSystems, a global leader in information technology platforms for health, business and government applications, today announced that MediWay Technology, one of the largest healthcare software companies in China, has built and deployed its new iMedical Cloud healthcare IT ecosystem platform using InterSystems IRIS for Health™. IRIS for Health, the only unified data platform engineered specifically for healthcare, empowers MediWay to support all stakeholders in the Chinese healthcare system – including government, healthcare organisations, and consumers – in an environment where medical reform policies are driving increased collaboration, information sharing and use of big data. MediWay’s iMedical healthcare information system (HIS) is used by around 500 healthcare organisations, including more than 300 tertiary hospitals and 30 top-100 hospitals in China. To accelerate the digital transformation of healthcare, however, MediWay and its partner Tencent Cloud require higher levels of accessibility, scalability and interoperability. Two iMedical Cloud applications, available to all healthcare stakeholders hosted on Tencent Cloud, have been launched with two core functionalities – transactional cloud collaboration (Cloud HIS) and data cloud collaboration (HealthChain). iMedical Cloud can be used within a region for real-time healthcare information exchange, centralised management control and unified allocation of resources. IRIS for Health supports the vastly increased data volumes required with features like sharding. This distributes data across a number of cloud-based servers to provide flexible, inexpensive performance scaling. “A cloud solution solves many pain points in healthcare,” said William Han, Chairman and CEO of MediWay Technology. “For example, it can provide a healthcare information system for county clinics, community healthcare centres and small-to-medium sized hospitals without the need for computer rooms, local servers or maintenance staff. By supporting our strategic pivot, InterSystems and its IRIS for Health technology have yet again shown the true partnership we’ve come to expect after 20 years of collaboration.” IRIS for Health empowers healthcare organisations with a unified data platform that combines analytical and transaction processing with native interoperability for all data types, including seamless transitions between healthcare-specific standards such as HL7 FHIR (Health Level Seven Fast Healthcare Interoperability Resources). IRIS for Health’s support for cloud-first development using container technology also allows MediWay Technology to take full advantage of the strategic partnership between its parent company, DHC Software, and Tencent Cloud. This enables MediWay to continue to integrate technologies such as Artificial Intelligence, blockchain, and speech input with its cloud-based healthcare solution. DHC Software became one of InterSystems’ first partners in China more than 20 years ago, and developed the original iMedical hospital information system on InterSystems data platforms. “During two decades of partnership, InterSystems has witnessed the fast growth of DHC Software and MediWay Technology, and we are very proud to see our latest data platform technology empower them to accelerate the digital transformation of healthcare,” said Luciano Brustia, Country Manager for Australia and Greater China, InterSystems. “InterSystems and our partners are committed to implementing the medical reform policies in China by promoting new healthcare approaches such as consortiums, making sure that each and every citizen benefits from better healthcare services and a healthy future.” About MediWay Technology MediWay Technology Co., Ltd. was incorporated in 2012, with a registered capital of RMB 100 million. It has a workforce numbering 2,200, and its predecessor is the Healthcare Business Unit of DHC Software founded in 1999. Over the past 20 years or so, MediWay has provided more than 500 hospitals, hospital consortiums, insurers, health commissions, social security bureaus and other relevant institutions with a variety of products and solutions, including the smart hospital solutions family, regional healthcare solutions family, Internet-based healthcare solutions family, and integrated Medicare payment and cost control solutions family. MediWay makes the most of the latest IT technologies to create and update its portfolios of products and solutions, is committed to achieving software as a service, and leverages its new thinking and ideas to support a sustainable healthcare industry. About InterSystems InterSystems is the engine behind the world’s most important applications. In healthcare, finance, government, and other sectors where lives and livelihoods are at stake, InterSystems is the power behind what matters™. Founded in 1978, InterSystems is a privately held company headquartered in Cambridge, Massachusetts (USA), with offices worldwide, and its software products are used daily by millions of people in more than 80 countries. For more information, visit InterSystems.com. Camp Quality Convoy Victoria returns to the road again for children’s cancer 2019-03-19T02:44:28Z camp-quality-convoy-victoria-returns-to-the-road-again-for-childrens-cancer I hope you're having a good day. We're reaching out to you today to see if you can help us generate interest for a very valuable children's charity... Camp Quality. The charity is once again hosting its Camp Quality Convoy Victoria to raise much funds to help children and families touched by cancer. Can you help us spread the word and generate some registrations amongst truck drivers and motorcyclists? A full press release is below (and attached). Below the press release is a dropbox link for images, and associated captions. If you need any of these images compressed and emailed direct please don't hesitate to ask. Kind regards, Alison Treloar Senior Account Manager Seftons 0422 093 639 alison.treloar@seftons.com.au Issue date: 19 March 2019 Camp Quality Convoy Victoria returns to the road again for children’s cancer It’s back! The Camp Quality Convoy Victoria will hit the road again on Sunday 7 April after a year off, with dozens of trucks and motorbikes expected to join the fun at Avalon Airport. Australia’s leading provider of aftermarket truck and trailer parts, Truckline has announced it will continue its generous support of the event and is also entering a special guest in the Convoy. The new International Pro-star demonstration truck will take a break from its tour around Victoria to feature in the day’s activities and is expected to draw a lot of interest from truck enthusiasts. For Truckline’s Territory Business Manager (VIC/TAS) Casey Stewart, this event holds special meaning for her and her family, after sadly losing her niece to childhood cancer at just five years of age. “I’m proud that Truckline is continuing their support of and involvement in this event and to see it back again after a hugely successful 2017 Convoy. It was a terrible tragedy for my family when we lost my niece, so I’m keen to do anything I can to support other families living with cancer,” Casey said. “Camp Quality is an incredible organisation that does so much for children growing up with cancer and their families. The programs and services offered to these children and their parents and siblings have a lasting impact and are such a great help through such a difficult time.” Camp Quality State Manager for Victoria, Tasmania and South Australia, Kendra Overall acknowledged that continued support from Truckline and other sponsors allowed the event to return and focus on raising as much money as possible. “With the ongoing support from Truckline and principal partner Viva Energy, we wouldn’t be able to hold an event like the Convoy and raise the money we do. Having corporate sponsors means all the funds raised by the truck drivers, the motorbike riders and the community at large supports Victorian kids to help children 0-13 deal with their own diagnosis, or the diagnosis of someone they love, like a brother, sister, mum or dad. We are there for them through the daily ups and downs of cancer. We create opportunities for the kids to be kids again: in-hospital, at home, at school and away from it all.,” Kendra said. “In the words of a family member: Camp Quality provides us with the opportunity to escape the daily treadmill of everyday life. To have smiles and laugher in the midst of a dark time is priceless.” Kendra told us. After a year off, this year’s Convoy will proceed slightly differently from earlier events, including the introduction of a Show and Shine following previous feedback. Registration fees for trucks and motorbikes in the Convoy are also substantially reduced this year, making the convoy accessible for participants, with all Convoy entrants encouraged to use the event to drive fundraising from their own networks. The Convoy will start from Avalon Airport at 8:00am on April 7, arriving back at the airport around midday where the Show and Shine and a range of family-friendly events will take place, including face painting for the kids, courtesy of sponsor Truckline. General entry is a gold coin donation, which includes the family activities on-site, and a raffle will be conducted to support the fundraising initiative. The day will conclude at 3pm. To register for the Convoy, go the website convoy.org.au ENDS About Truckline Truckline is Australia’s largest retailer of aftermarket truck and trailer parts, supporting all makes and models of North American, European and Japanese commercial vehicles. During the company’s 60 years servicing the Australian trucking industry, Truckline has built an extensive network of 22 company owned stores nationally, all with warehousing facilities. Owned by CNH Industrial, Truckline sources renowned products from leading suppliers around the world to cater for Australia’s unique conditions and climate. With a catalogue of more than 25,000 competitively priced parts and accessories, Truckline caters for all road transport needs. Whatever the age, make or model of the truck or trailer, Truckline’s highly skilled team is dedicated to providing parts to fulfil each customer’s requirement. Truckline is committed to keeping its customers moving. PHOTOS A dropbox link for photos is here: https://www.dropbox.com/sh/b03o5kzh1imzddx/AAAgtw51eknvp4dInvpXWE2na?dl=0 Captions are as follows (easily referenced with filenames): 1. Sponsor Truckline will be entering the new International ProStar demonstration truck in the convoy 2. Truckline’s Casey Stewart whose family has experienced their own childhood cancer tragedy 3. Truckline VIC TAS Territory Business Manager Casey Stewart with Truckline Hallam Manager Ian Miles 4. Truckline's Casey Stewart with the International ProStar demonstration truck which will join the Convoy 5. On the road at past Camp Quality Convoys 6. The line up from past Camp Quality Convoys 7. All parked up at previous Camp Quality Convoys 8. Truck drivers and motorbike riders alike gather for Convoy HEMIDEINA RECEIVES FEDERAL GOVERNMENT ACCELERATING COMMERCIALISATION GRANT FOR THE HERA WIRELESS IMPLANT 2019-03-14T22:34:16Z hemideina-receives-federal-government-accelerating-commercialisation-grant-for-the-hera-wireless-implant MELBOURNE, March 15, 2019: Hemideina, a hearing solutions company focussed on the development and commercialisation of the Hera Wireless Implant, announced today that it was awarded an $800,000 grant from Accelerating Commercialisation, under the Australian Government’s Entrepreneurs’ Programme.   The funding will enable Hemideina to strengthen its Intellectual Property portfolio, plan market access pathways, and trial the Hera Wireless Implant device for safety and efficacy.    Dr Elizabeth Williams, CEO and Co-Founder of Hemideina said: “The Accelerating Commercialisation grants are very competitive. Receiving the grant is a significant milestone for Hemideina, and further validates our design capabilities and capacity to disrupt the established hearing implant market with a second-generation alternative.”   Dr Kate Lomas, Co-Founder and Chief Scientific Officer, describing the Company’s patented acoustic technology, said: “We have an opportunity to bring this technology to the market, which should seed further Australian-based technology innovations for people with unmet needs in hearing solutions.”    Andrew Maxwell, Chairman of the Board, said: “The Accelerating Commercialisation program is critical to the success of Australia’s well-respected innovation eco-system. Companies like Hemideina, undertaking early commercialisation of essential products for the global human health sector, urge all levels of government to continue to champion research and development incentives of this kind.    “Accelerating Commercialisation, coupled with the R&D Tax Incentive, are vital for Australia to build companies that will create a sustainable industry and jobs-based innovation in human healthcare. Together, we can be the architects of more Australian success stories by driving competitiveness and economic returns and accelerating sustainable progress with these incentives.”                About Hemideina   Founded in 2017 with a mission to revolutionise hearing for the profoundly deaf, Hemideina takes inspiration from biological systems to deliver solutions in human hearing. Hemideina’s Hera Wireless Implant is based on the company’s proprietary signal processing technology and is set to disrupt the hearing implant market currently worth $1.8bn.    Media contact:Georgie MorellMorell & Co0438 008 383georgie@morellandco.com   For more information, please visit www.hemideina.com. Intermittent Fasting With Calocurb 2019-03-10T22:05:16Z intermittent-fasting-with-calocurb Calocurb have some great ideas on how to manage intermittent fasting, which are designed to work alongside Calocurb to help you reach your specific goals. This ancient eating technique is surprisingly simple, sustainable and is helping people lose weight and live healthier. It is basically a pattern of eating that switches between periods of eating and not-eating (fasting). Intermittent fasting is about when you eat, not what you eat. Don’t think about it like a conventional diet as it’s more like an eating pattern. With the burgeoning plethora of fast food outlets, cafes and restaurants, food is absolutely everywhere, which means our eating styles just aren’t in sync with our evolution. As a result, we’re missing out on the benefits of intermittent eating to improve health, protect against disease and manage weight. Several scientific studies have confirmed what we’ve long known – intermittent fasting really can support weight management and a healthy body. However, before you start you should check with your doctor as to whether intermittent fasting is right for you. Calocurb recommend you should prepare to manage your hunger by eating healthy, whole foods for your last eating meal, a schedule of activities to keep you on-the-move and a natural supplement like calocurb to stay in control through your fast.  You can also find support through friends, or Calocurb’s happy healthy living support group on Facebook. There are plenty of places to find more fasting information and tips too. They recommend that you maintain the healthy things in your life, such as exercise, and you should keep up with your extra-curricular activities, and hydrate with water. You can slowly increase your fast by delaying your fast-breaking meal just an hour or two at the start. Your body will slowly adapt to the new routine, and natural supplements like Calocurb can help you stick to intermittent fasting. This 100% plant-based supplement uses hop flowers to help you manage hunger, control cravings and stay focused when you need it most, so for more information on where can I buy Calocurb, what is Calocurb, Calocurb reviews and appetite suppressants NZreviews please go to www.calocurb.co.nz . Dental Greeting Offers No-Cost and Low-Cost Care for Children 2019-03-08T02:03:16Z dental-greeting-offers-no-cost-and-low-cost-care-for-children Dental Greetings knows the importance of early dental care for children to facilitate a lifetime of good oral hygiene. The practice offers up to $1,000 in select dental treatments over two years for children that are CDBS eligible. One of the keys to a beautiful, healthy smile is preventative treatments and Dental Greetings offers some services at a discounted fixed rate, in addition to no-gap or nothing-to-pay services for health fund patients. For children who aren’t CDBS eligible, the cost is just $99 and includes a check-up, cleaning, and x-rays if needed. For parents that aren’t sure if their child qualifies, they can call the office or stop in and the practice’s helpful staff will assist them in finding out. Many children don’t obtain the preventative check-ups and care they need. The Banyo dentist wants to make oral health treatments as easy and affordable as possible for everyone. The benefits and necessity of pediatric dentistry is often overlooked. Some conditions are obvious, but many are not. Children often clench or grind their teeth at night. It causes wear and tear on their teeth that can result in permanent damage to their adult teeth, along with headaches, disrupted sleep and even problems with their jaw joints. A popular myth is that baby teeth don’t need much care since they’ll later make way for adult teeth, but the opposite is true. Baby teeth are weaker than adult teeth and the enamel is 50 percent thinner. The dentist Wavell Heights knows how easy it is for decay to set in on baby teeth. Gum disease is something that people normally associate with adults, but the condition also affects children. The gums are responsible for protecting bone that holds teeth in place. Gum disease weakens that structure and teeth may shift. It can cause inflammation, swelling, and bleeding when children brush their teeth. The special offer at Dental Greetings for children that are CDBS eligible helps youngsters obtain the dental care they need at little or no cost and establishes the foundation of good oral health throughout their lifetime. Early dental exams by the Geebung dentist are an investment in a child’s health that also has far-reaching benefits on their physical, social, mental and emotional development. About Dental Greetings Founded by a husband and wife duo, Dental Greetings is dedicated to providing a family approach that treats patients with the utmost care and understanding. Dental services are available throughout Virginia, Banyo, Wavell Heights, Boondall, Toombul, Zillmere, Nudgee, Nudgee Beach, Northgate, Nundah, Geebung and all surrounding suburbs on the Brisbane north side. Dental Greetings will change the way you think of dentists and we aim to make any dental phobia a thing of the past. Connect with Dental Greetings on Facebook and Instagram. Media Contact Dental Greetings Phone: 07 3124 7166 Website: http://dentalgreetings.com.au Australian Skincare Product Brings Home Editor’s Choice in 2019 Beauty Shortlist Awards… Again! 
 2019-03-06T03:08:40Z australian-skincare-product-brings-home-editors-choice-in-2019-beauty-shortlist-awards-again FOR IMMEDIATE RELEASE
 6th March 2019 The Annual Beauty Shortlist Awards has announced the winners after six months of thoroughly testing ethical, natural and eco-friendly beauty products from over 30 countries. Since starting in 2012 in the UK, the awards have become the most trusted in the industry by consumers. Claiming to be 100% sponsorship, advertisement and partnership free, the aim is to actively seek out ethical brands on the market and undergo intense testing and judging by an international judging panel of industry leaders from the UK, USA and Australia. Paudha Healing was created by Valley Heights local Renee Tilley while studying a Bachelor of Health Science (Naturopathy). Renee discovered the incredible healing properties of herbs and plants growing wild and in abundance around her home in the Blue Mountains - often being considered weeds! Renee went on to study cosmetic chemistry to combine her in depth knowledge of herbs with advanced chemical formulations to create skincare products that were safe and effective for all skin types. Hand made in the Blue Mountains using locally sourced Australian Certified Organic ingredients wherever possible and accredited as a cruelty free skincare company by Choose Cruelty Free Australia. Paudha Healing’s Nourish & Repair Face Oil also won the Editor’s Choice Award in 2017. This blend has been carefully selected to provide deep healing and moisturizing, fight signs of premature ageing, reduce redness and is suitable for ALL skin types. “Our Nourish & Repair Face Oil continues to be one of our top selling products each month and winning this award back in 2017 and for the second time in 2019, really confirms what our customers are saying about this amazing oil.” Says Renee Tilley, Owner and Director of Paudha Healing. Nourish & Repair Face Oil Contains: Certified Organic Jojoba Oil Certified Organic Rosehip CO2 Extract Certified Organic Calendula Flower Extract Certified Organic Sunflower Seed Oil Certified Organic Rosemary Extract Certified Organic Frankincense Essential Oil Rose Geranium Essential Oil RRP: $33 for 30mls. For more information on this multi award-winning product click here. Paudha Healing is looking to expand its network of retail stockists with the goal of being readily available in all states across Australia and New Zealand by the end of 2019. “I have been using this oil now for over 12 months and am totally thrilled with the results! I used to use a good quality anti aging cream but this oil is giving me better results by far! I love this product so much” Karmell via website. “5 stars plus for this amazing oil. After turning 40 I found my skin changed dramatically, becoming dry and showing sun spots. After using this oil for a month, my spots are disappearing and my skin feels nourished and glowing. I no longer wear foundation on a day to day basis. I am in love with this product!” Nicole via website. For samples or media enquiries contact: Renee Tilley Owner/Director Paudha Healing 0416 212 889 info@paudhahealing.com.au CarePlus™ Direct is here, ensuring Nurse Call is more accessible for smaller clinics and Managers 2019-03-05T00:50:37Z careplus-direct-is-here-ensuring-nurse-call-is-more-accessible-for-smaller-clinics-and-managers-1 CarePlus™ Nurse Call is expanding how its global healthcare solutions and services are delivered with the launch of our brand-new website, CarePlus™ Direct. The new online destination supplies Nurse Call systems directly to General Managers, Clinical Operations Managers and Directors of Nursing at smaller clinics, such as day surgeries and small aged care facilities, for the first time by cutting out the middle man and utilising your facility’s onsite technician.   Our goal is to provide an advanced and superior solution in a cost-effective package without the fuss. CarePlus™ Direct addresses the fundamental challenges in the healthcare industry, extending the accessibility of our technology that has been carefully designed for smaller medical clinics and day surgeries.   A comprehensive care management solution is customisable online and can be installed by in-house technical personnel via extremely simple instructions and minimal real-estate. Auto-configuration software saves budget costs, reduces labour payments, and eliminates disruption to facilities from installation crews.   Andrew Rothon, the founder of CarePlus™, understands functionality is key. “Wired and Wireless options are available for each facility’s needs, and we master scalable, patient-centric features to maintain patient and staff satisfaction for fostering a reliable healing and working environment.” Each Nurse Call solution provides increased productivity and high-acuity workflow whilst limiting administration load and decreasing patient waiting and treatment times.   Our solutions maintain communication integrity at very cost-effective rates. For more information, please visit CarePlus™ Direct. Melbourne Start-up, hayylo, named a Finalist in 7th Asia Pacific Eldercare Innovation Awards 2019-03-04T23:34:10Z melbourne-start-up-hayylo-named-a-finalist-in-7th-asia-pacific-eldercare-innovation-awards February 28, 2019 - hayylo was named a Finalist in the Best Smart Care Technology - Solution category, and joint Finalist with integratedliving Australia in the Innovation of the Year - Care Model category in the 7th Asia Pacific Eldercare Innovation Awards. The annual Asia Pacific Eldercare Innovation Awards were created to recognise the achievements of organisations that promote innovative business, operational and service delivery practices that shape the eldercare industry and seek to improve people’s experience of ageing. The awards are held during the International Ageing Week in Singapore, in conjunction with the annual International Ageing Asia Innovation Forum, and are open to businesses across the Asia Pacific region. hayylo is a Finalist in two of the fourteen categories presented at the awards this year, where category themes include best innovation of the year, best operator, best ageing program, best smart care technology, and best product to support ageing. With continued growth across Australia and imminent expansion into New Zealand and Asia, hayylo is quickly becoming the new benchmark in customer communication, with over 20,000+ regular end users of the platform and app. Having recently won the ITAC2018 awards for Best Solution Providing Consumer Independence and Joint Overall Winner for 2018, hayylo founders Gregory Satur and Simon Heaysman are excited to contend for the Asia Pacific Eldercare Innovation Awards. “To be recognized again for our work around bringing together fragmented health information into a consolidated channel for customers and their families, shows how invested the community services sector is around solving not only for today but the future. In the backdrop of the Royal Commission, we see this as such a positive story around how technology and the desire to help societies most vulnerable people, can be fused together for great outcomes. We look forward to continuing to support communities across Australia and around the world”. Said Gregory Satur, CEO and Co-founder at hayylo. Winners will be announced at the awards ceremony on 15 May 2019 by a distinguished panel of international judges. Nominated organisations and stakeholders from the Asia Pacific health and elder care sector are expected to attend. Since its launch in 2016, hayylo has become an industry leader in aged, disability and home health care innovation. hayylo’s cloud and mobile based technology helps care providers deliver better care to their customers through data integration and enhanced communication features. hayylo continues to develop consumer features to help people enjoy better health and wellbeing, and remain independent and supported at home, for longer. www.hayylo.com Contact: Simon Heaysman, COO and Co-founder at hayylo sheaysman@hayylo.com1300 657 983 OXAIR’S PSA SYSTEM SUPPLIES CONSISTENT LIFELINE FOR INDIAN HOSPITAL 2019-03-04T13:13:41Z oxair-s-psa-system-supplies-consistent-lifeline-for-indian-hospital PSA is a unique process that separates oxygen from compressed air. The gas is then conditioned and filtered before being stored in a buffer tank to be piped directly to the end user on demand or to refill bottles already in circulation. Oxair Gas Systems India successfully installed the oxygen production system, which generates the life-saving gas directly from the atmosphere with constant purity of up to 95%, at the Samarth Hospital, a highly-regarded medical facility in the state of Maharashtra that had been using up to six oxygen cylinders a day. Investing in the Oxair PSA system releases Samarth Hospital from the inconvenience and expense of shipping in replacement cylinders of the gas, as well as reduce the health and safety risk to employees from handling them within the facility. Like many hospitals space was at a premium at Samarth, to overcome this challenge Agastya sited the equipment in the basement where there was sufficient ventilation. The medical facility now boasts oxygen on tap directly supplying ventilators supporting patients with their breathing. PSA plants are gaining traction within the medical fraternity in India as they bring control of oxygen in-house, eliminating handling of cylinders and the reliance on outsourcing. Oxair’s units not only bring substantial cost savings and convenience, but guarantee that extreme situations like weather events cannot leave patients vulnerable to failing supplies. Dr. Suhas Kalshetty, an intensive care doctor at the Samarth Hospital, said: “The new oxygen system is helping to deliver improved healthcare for the people of Pune – it offers a consistent and sustainable source of pure oxygen which is helping to save patients’ lives.”  Oxair’s PSA systems are high quality medical devices, fully compliant under regulation ISO 13485 for use in all hospitals and healthcare facilities. The equipment is designed to last and deliver high purity oxygen to hospitals and healthcare facilities in even the remotest locations around the world. Sourcing conventional oxygen cylinders can be a drain on hospital resources, Oxair is spearheading the drive on the Subcontinent for a safer, cleaner and more robust method of delivering this life-saving gas that will enable medical facilities to be self-sufficient in generating the purest of oxygen for years to come. As well as India, patients worldwide are benefitting from Oxair’s units which have also been installed in hospitals in Africa, the Philippines, Tonga, and Indonesia to provide a reliable and sustainable supply of oxygen NutraFuels, Inc Explores New Delivery Systems with Pharmaceutical GMP Manufacturer 2019-03-01T15:36:34Z nutrafuels-inc-explores-new-delivery-systems-with-pharmaceutical-gmp-manufacturer Coconut Creek, FL, Mar 1, 2019 - (ACN Newswire) - via NEWMEDIAWIRE -- NutraFuels, Inc. (fka NutraLife Biosciences, Inc.) plans to explore additional options for delivery systems for its nutraceutical and wellness products and pharmaceutical delivery systems."We are excited to be exploring our capabilities in the life sciences space by engaging in the research and development of more formulations and enhanced delivery systems with an experienced cGMP pharmaceutical manufacturer," said Edgar Ward, CEO and Founder of NutraFuels.The Company plans to explore these various pharmaceutical formulations and delivery systems while utilizing the valuable experience of a cGMP pharmaceutical manufacturer.NutraFuels manufactures and distributes private label and its own branded products under its NutraHempCBD and NutraSpray brands. The Company's product development, testing and research are conducted by four chemists under the supervision of Mr. Ward. The Company manufactures 100% of its products at its FDA registered facility in accordance with GMP standards.NutraFuels, Inc. (OTCQB: NTFU) is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (SEC). As filed with the SEC on November 13, 2018, the Company's financial results for the three (3) and nine (9) month period ended September 30, 2018 saw revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NutraFuel's filings with the SEC can be viewed at www.sec.gov, or on the Company website at www.NutraFuels.com.NTFU's CBD products and information about the company's direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.Contact:NutraLife Biosciences, Inc. Coconut Creek, FL 33073 Telephone 1-888-509-8901 http://www.NutraFuels.comForward-Looking StatementsThis communication contains statements of a forward-looking nature about NutraFuels, Inc. (the "Company"). These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. New risk factors emerge from time to time, and it is impossible for the Company's management to predict all risk factors, nor can the Company assess the impact of all factors on Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.Source: NutraFuels Inc.  NutraFuels, Inc Tests Confirm High Quality Proprietary Ultra Shear Technology Platform 2019-02-26T12:57:37Z nutrafuels-inc-tests-confirm-high-quality-proprietary-ultra-shear-technology-platform Feb 26, 2019 - NutraFuels, Inc (NTFU) and Pressure BioSciences, Inc (PBI), in a joint venture, announce that analytical tests on Hemp-derived CBD oil processed by PBI's Ultra Shear Technology (UST) platform confirm: (i) UST processing results in the development of a true CBD oil nanoemulsion, and (ii) CBD is neither lost nor modified during the UST process (> 99% recovery).The proprietary UST platform combines ultra-high pressure with extreme shearing forces to create very small, nano-scale mixtures of fluids that otherwise do not mix, resulting in a highly stable homogenized solution called nanoemulsions.Dr. Vera Gross, Senior Scientist R&D at PBI, commented: "To determine if the UST process resulted in a loss or modification of CBD during processing, we enlisted the help of our collaborator NutraFuels, Inc. NTFU has an FDA-inspected, highly-qualified analytical laboratory with state-of-the-art equipment and well-trained chemists with years of experience in laboratory testing."For many oil-based nutritional and therapeutic products, such as CBD-infused nutraceuticals, nanoemulsions offer superior water solubility and increased bioavailability for improved absorption. Consequently, there is a significant need to develop reliable, scalable methods to process CBD oil into high-quality nanoemulsions, with minimal loss of CBD during the process.Mr. Cooper Dodd, an R&D Scientist at NTFU, said: "Using a powerful laboratory method called HPLC to measure the concentrations of CBD and potential impurities, we determined that no appreciable amount of CBD was lost during the UST process. These results compare well to our standard processing method of ultrasonication, which can carry a risk of measurable loss of CBD, and sometimes create the appearance of impurities if not performed properly. While there is more work to be done, as a nutraceutical manufacturer with products already on the market, we see these results as a robust leap towards better optimization of our CBD-enhanced products."Dr. Gross, Director of Applications Development from PBI, added: "To determine if UST processing of CBD oil generates true nanoemulsions, we asked an independent, university-affiliated laboratory to determine the size of oil droplets in post-UST processed material using a universally-accepted sizing method called DLS. Their results showed that post-UST processed oil droplets were approximately 65 nm in size, well within the range of 20-200 nm generally accepted as defining a true nanoemulsion (Nano- and Microscale Drug Delivery Systems, 2017)."Professor Keith Warriner, Professor of Food Science at the University of Guelph, and a recognized expert in the cannabis industry, commented: "The data disclosed today on UST-generated nanoemulsions of CBD oil are very impressive. Creating nanoemulsions of CBD oil with full preservation of CBD throughout the process, while not generating impurities, remains a significant challenge in the industry. These data offer great promise to the future."Professor Warriner continued: "Although there is great excitement over CBD-infused edibles and beverages, and rightfully so, I believe that CBD-infused topicals may be an even greater market for CBD products in the near future. However, to be successful, it is imperative that topicals be highly stable, bioavailable and readily absorbent nanoemulsions. After a review of the data released today, the UST process appears to be a leading candidate to fill that need."Dr. Bradford A. Young, Chief Commercial Officer of PBI, commented: "We were very excited to share the news just last week of PBI's visually obvious successful production of water-soluble CBD Oil. However, the addition of these scientific validations of our successful achievement of creating nanoemulsions by the UST platform, and our preservation of CBD levels all the way through to the finished product are frankly the crowning touch to the news of these accomplishments. We believe our proprietary Ultra Shear Technology will be a pivotal change agent strongly affecting the future of many major existing product areas, spanning foods, nutraceuticals, therapeutics, cosmetics, lubricants, paints, and other industries."About NutraFuels, Inc.NutraFuels, Inc. fka NutraLife BioSciences, Inc. (OTCQB: NTFU) was founded in 2010 and has evolved into a branded and private label developer, distributor and Food and Drug Administration registered (FDA) manufacturer. NTFU's products include a range of nutraceutical, wellness, and CBD products as well as a cosmetics line. NutraFuels' manufacturing process received the Good Manufacturing Processes Standard (GMP) certification. Its products adhere to high manufacturing standards throughout every step of the manufacturing and extraction process. NTFU's product testing and research and development are conducted by four chemists under the direction of NTFU's founder and Chief Executive Officer, Edgar Ward.About Pressure BioSciences, Inc.Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. PBIO's products are based on the unique properties of both constant (i.e. static) and alternating (i.e. pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g. cell lysis, biomolecule extraction). PBIO's primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications.Source: NutraFuels Inc. MedAdvisor Announce HY19 Interim Results 2019-02-26T03:04:53Z medadvisor-announce-hy19-interim-results Melbourne, 26 February 2019 -- MedAdvisor Limited (ASX: MDR, the Company, has released its Appendix 4D and is pleased to provide its Financial Report for the 6-month period ending 31 December 2018 (H1 FY2019). Financial Overview Revenue from continuing ordinary activities of $3.88m, up 19% on the prior corresponding period. Total revenue was $3.96m and the Company continues to operate at a high gross margin of 87.6% in line with prior periods and management expectations. The strong revenue growth compared to the prior period has been driven by significant pharmacy network growth. The company has ~3,200 pharmacies connected to the platform. This growth has resulted in more SaaS revenue and more patient growth in Patient Engagement Programs.  Due to continued growth in the SaaS based revenue streams from a growing pharmacy base has resulted in SaaS based fees climb to 65% as a percentage of total (H1 FY18 was 61%), with User Based revenue equating to 35% of revenue.  Gross margin performance of 87.6% means that the growth in revenue supports the investments the business is making in new markets both locally and abroad that will deliver revenue in future periods. Financial Performance Overview   Metric HY FY 17 HY FY18 HY FY19 18/19 growth % Operating Revenue $1.5m $3.2m $3.9m 19% Gross Margin 83% 88% 87.6% ~ Core Business EBITDA ($1.24m) $0.2m $0.98m 376% Investment Opex $2.0m $2.4m $5.4m 126% Reported EBITDA ($2.0m) ($2.2m) ($4.4m) 103% Source: MedAdvisor   Australian Operational Overview   HY 18 HY 19 % Change Total connected patients at period end 0.96m 1.1m 14.6% Average number of patients per pharmacy ~312 ~388 24.4% Value of scripts processed via TTR/GP Connect during half $126m $154m 22.2% Number of Patient Engagement Programs 26 33 26.9% Source: MedAdvisor Over 1,100,000 patients were connected to MedAdvisor’s platform as at 31 December 2018. The opportunity to help another 11m patients in Australia who live with a chronic disease is a key focus for the Australian business. Revenue from Patient Engagement Programs (PEPs) increased by 16.4% compared to the same period last year. The growth of our patient user base continues to drive Australia’s largest medication manufacturers to MedAdvisor with a total of 33 programs contracted to the platform over the period. MedAdvisor serviced 17 manufacturers over the period, three of which have now been working with MedAdvisor for three years, to communicate with patients and improve their health. This follows strong growth in 2017 and MedAdvisor had a record month for PEP billings in December 2018, for which revenue will be recognized in future periods. MedAdvisor’s Health Services Hub can facilitate face-to-face intervention and education programs alongside digital engagement programs to improve the health of relevant patient populations. This means that not only can these program funders run targeted programs to the 1.1m digitally connected patients, they can access a further ~7.6m in-store. Services, including Government funded 6CPA programs recorded in PlusOne by MedAdvisor grew strongly at 280% on the prior year, highlighting significant growth in pharmacies broader engagement with the platform through the Health Services Hub.   Technology Enhancements MedAdvisor is now ISO27001 compliant and we have aligned our compliance program to address the US HIPAA (Health Insurance Probability and Accountability Act) regulations. This investment is supporting business development activities and will result in a global market ready platform available in April that is equipped for deployment and revenue generation. The new platform will be deployed in Australia in time, and the new security and compliance practices will deliver immediate improvements.   International Expansion The Company is investing to expand its business internationally. MedAdvisor is now two thirds of the way through its initial international scale up spend which is due to be finalised in Q3 2019. The work performed so far is on plan and on budget. This investment will deliver significant benefits to the business, both domestically and as we scale up internationally, streamlining our offerings in multiple markets. The Global Health Services Hub product has a wide application and is built on an efficient updated technology platform.   US Founder, Mr Josh Swinnerton, has relocated to the United States, joining the team there, and will play a key role in developing the product for market entry, leveraging his deep understanding of the business and background in the US market. MedAdvisor appointed Mr Jim Rotsart and Mr Luke Merrow as US based executive advisors with extensive expertise in patient engaging health services to further power the US business. Jim and Luke are highly experienced and networked in the key focus areas for MedAdvisor in the US being pharmacy chains, manufacturers and insurers, providing valuable in market relationships to MedAdvisor. Asia MedAdvisor announced the signing of the MOU with Zuellig Pharma (announced: 3 December 2018) defining the framework for a 50/50 Joint Venture to enter 8 Asian markets. Zuellig is a ~US$12B turnover business focusing on wholesale distribution of medicines, medication adherence programs and diversified healthcare. Zuellig distributes to ~350,000 pharmacies, GP’s and Hospitals in these countries with a market of over 560 million people, providing an outstanding opportunity for MedAdvisor. MedAdvisor expects to sign the long form documents in Q3FY19.   Corporate update During the half, MedAdvisor announced the introduction of its Clinical Trial Recruitment (CTR) service to existing and new clients. MedAdvisor can identify suitable patients for clinical trials that will help accelerate access to new and novel medicines in Australia. With 80% of clinical trials experiencing a delay due to patient recruitment, MedAdvisor has an important role to play in this $2bn industry. In September, MedAdvisor appointed, Ms Ruba El-Afifi to the role of EGM People & Culture. Ruba has a history in senior HR roles and most recently from Oracle’s Aconex where she was GM Human Resources. In December the company signed an agreement with Thrivor a SaaS platform delivered through web-browser and app interface focused on assisting patients and their families when dealing with a serious illness. The administration portal is designed to assist health institutions manage communications, appointment facilitation and payments for outpatients. MedAdvisor was awarded 5% of the Equity in Thrivor for work completed during the half.  Further commercial opportunities with this partnership will be through Clinical Trial Recruitment and support via Patient Programs. Mr Robert Read said “Domestically we are continuing to add more breadth to our pharmacy and GP offerings to increase engagement with these core customer groups and our network continues to expand. Globally, the business is laying the right foundations for international expansion and we will have our product ready for the US market this financial year. Our new Health Services Hub will allow us to run medication programs to highly targeted patient populations around the globe including in South East Asia through our new partnership with Zuellig Pharma.” ---ENDS---  For More Information Jennifer Duraisingam Corporate Communications Manager Tel: +61 3 9095 3036 jenniferd@medadvisor.com.au     About MedAdvisor MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. Founded with a desire to simplify medication management, the highly automated and intuitive Australian software system connects patients to their community pharmacy, providing them with real time access to their personal medication records. Available free on mobile and internet devices, the platform also incorporates a variety of valuable and convenient features including reminders and pre-ordering of medications, which together improves adherence to chronic medications by approximately 20%. Since launching in 2013, MedAdvisor has welcomed over one million users through its connections with ~55% of pharmacies and a network of thousands of GPs across Australia. MedAdvisor was recognised in the 2018 AFR Fast 100 at position 23. Breakthrough chronic lymphocytic leukaemia (CLL) treatment now available for Australians 2019-02-25T06:51:23Z breakthrough-chronic-lymphocytic-leukaemia-cll-treatment-now-available-for-australians The Leukaemia Foundation welcomes the Federal Government’s announcement that the targeted cancer treatment Venetoclax (Venclexta®), will be added to Pharmaceutical Benefits Scheme (PBS) from 1 March 2019.    Venetoclax will be available in combination with rituximab for patients aged 18 years or older with relapsed or refractory chronic lymphocytic leukaemia (CLL), who have received at least one prior CLL therapy and who are unsuitable for treatment or retreatment with a purine analogue.     CLL is the most common form of leukaemia with close to 1,500 Australians expected to be diagnosed this year. It is a slow growing leukaemia that affects white blood cells. Symptoms may include swollen lymph nodes (glands) in the neck, groin and arms, tiredness, unexplained bruising and unintentional weight loss.     The Leukaemia Foundation’s CEO, Bill Petch, said, “This is great news for Australians diagnosed with CLL. Having affordable access to breakthrough treatments is vital for improving quality of life and ultimately surviving their blood cancer.     “We continue to encourage the government to support targeted and innovative treatments ensuring Australians diagnosed with a blood cancer have affordable access as quickly as possible.” he said.    Venetoclax has been in development for over 30 years and is based on the Australian discovery that a protein called BCL-2 helps CLL cells survive. Blocking this protein helps to kill and reduce the number of these cancer cells and in turn may slow the spread of CLL.      The Leukaemia Foundation has been funding blood cancer research since 2002 supporting Australian research and researchers with more than $47 million in funding including early work on the precursor to ABT-199 which assisted in the development of Venetoclax.    For further CLL information, please download the Leukaemia Foundation information booklet https://www.leukaemia.org.au/wp-content/uploads/2017/08/CLL_WEB.pdf or contact your local Blood Cancer Support Coordinator on 1800 620 420.  -ENDS-  About The Leukaemia Foundation:  The Leukaemia Foundation is the only national charity dedicated to helping more Australians survive blood cancer and live a better quality of life. Leukaemia, lymphoma, myeloma and related blood disorders are all types of blood cancer, which can develop in anyone, of any age, at any time.   More than 100,000 Australians are living with blood cancer or related disorders, and the equivalent of one person every 41 minutes is diagnosed. Although research is improving survival, sadly an Australian loses their life to blood cancer every two hours, claiming more lives than breast cancer and melanoma.   For more information, please visit leukaemia.org.au   Dental Greetings Partners with Zip Money to Offer Interest Free Payment Plans 2019-02-22T04:40:58Z dental-greetings-partners-with-zip-money-to-offer-interest-free-payment-plans-1 Many people stay away from the dentist out of fear or trepidation about out-of-pocket costs. Dental Greetings has announced that it has partnered with ZIP Money for interest free repayments for dental treatment with no minimums and up to $5000 if required. While announcing the interest free payment plans the clinic also said, “At Dental Greetings we never want our patients to stay in pain or discomfort while trying to work a dental appointment into their budget. That is why we try to make dentistry as affordable as possible whilst also giving the highest level and quality of dental care.” Sharing further details about the plan Dr Jeffrey Xiao (BOralH, G. Dip. Dent (Griffith University, Gold Coast), owner and lead dentist at Dental Greetings elaborated about the dental care services offered by his clinic. Dental Greetings offers a full range of services for people of all ages, from pediatric dentistry and cosmetic solutions, to orthodontics and emergency dentistry. However we understand that sometimes some assistance is required which is why we offer interest free payment plans to all our patients if required. Cosmetic services for a celebrity smile are available at the Geebung dentist & dentist Wavell Heights encompassing orthodontics, crowns and bridges, teeth whitening, and restorative solutions to repair damaged teeth. Dental Greetings also performs root canals when necessary to eliminate pain and save a tooth. Invisalign® aligners are the removable, unobtrusive and gentle way to straighten teeth for teens and adults. The dentist Wavell Heights is a certified Invisalign® provider. There are no metal brackets or wires to tighten with Invisalign® aligners. About Dental Greetings Founded by a husband and wife duo, Dental Greetings is dedicated to providing a family approach that treats patients with the utmost care and understanding. Dental services are available throughout Virginia, Banyo, Wavell Heights, Boondall, Toombul, Zillmere, Nudgee, Nudgee Beach, Northgate, Nundah, Geebung and all surrounding suburbs on the Brisbane north side. Dental Greetings are leading Toombul dentist will change the way you think of dentists and we aim to make any dental phobia a thing of the past. Connect with Dental Greetings on Facebook and Instagram. Media Contact Dental Greetings Shop 6B/7 Toombul Road  Virginia QLD 4014 Phone: 07 3124 7166